Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …

Gliomas, the most common malignant primary brain tumours, remain universally lethal. Yet,
seminal discoveries in the past 5 years have clarified the anatomy, genetics and function of …

Importance Glioblastoma is the most lethal primary brain cancer. Clinical outcomes for
glioblastoma remain poor, and new treatments are needed. Objective To investigate …

Glioma is the most common primary cancer of the central nervous system, and around 50%
of patients present with the most aggressive form of the disease, glioblastoma. Conventional …

In this randomized phase II clinical trial, we evaluated the effectiveness of adding the TLR
agonists, poly-ICLC or resiquimod, to autologous tumor lysate-pulsed dendritic cell (ATL …

Glioblastoma is a highly lethal brain cancer with a median survival rate of less than 15
months when treated with the current standard of care, which consists of surgery …

Background Standard therapy for glioblastoma includes surgery, radiotherapy, and
temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate …

Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with a poor
prognosis, despite surgical resection combined with radio-and chemotherapy. The major …

Glioblastoma (GBM) is a highly malignant type of primary brain tumor with a high mortality
rate. Although the current standard therapy consists of surgery followed by radiation and …

Long-standing scarcity of efficacious treatments and tumor heterogeneity have contributed to
triple-negative breast cancer (TNBC), a subtype with a poor prognosis and aggressive …